Apabetalone , 97% , 1044870-39-4
| Pack Size | Price | Stock | Quantity |
| 1MG | RMB39.20 | In Stock |
|
| 5mg | RMB111.20 | In Stock |
|
| 10mg | RMB159.20 | In Stock |
|
| 25mg | RMB287.20 | In Stock |
|
| 50mg | RMB399.20 | In Stock |
|
| 100MG | RMB591.20 | In Stock |
|
| 250mg | RMB979.20 | In Stock |
|
| 1g | RMB2579.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Boiling point: | 594.2±60.0 °C(Predicted) |
| Density | 1.28±0.1 g/cm3(Predicted) |
| storage temp. | -20°C (des.) |
| solubility | Soluble in DMSO (up to 75 mg/ml) or in Ethanol (up to 4 mg/ml). |
| form | solid |
| pka | 14.21±0.10(Predicted) |
| color | White |
| Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month. |
Description and Uses
The bromodomain and extra terminal (BET) proteins interact with acetylated lysine-containing sequences on target proteins via their bromodomains, commonly altering gene transcription. The human BET proteins contain two bromodomains, the first (BD1) being closer to the N-terminus than the second (BD2). RVX-208 is a selective antagonist of BET bromodomains, binding with 10-100-fold higher affinity for BD2 (IC50 = 0.04-0.28 μM) over BD1 (IC50 = 1.8-3.1 μM). RVX-208 causes the selective release of BET proteins from chromatin in cells. It interferes with the BET protein BRD4, resulting in an increased expression of apolipoprotein (Apo) A1 in cells, mice, monkeys, and humans. RVX-208 also reduces atherosclerosis in hyperlipidemic ApoE-deficient mice.
RVX-208 is a selective antagonist of bromodomain and extra terminal (BET)’s bromodomains.
Safety
| Symbol(GHS) |  GHS08 |
| Signal word | Warning |
| Hazard statements | H371 |
| Precautionary statements | P260-P264-P270-P309+P311-P405-P501 |
